MA51337A - Inhibiteurs spiro exo-aza de l'interaction ménine-mll - Google Patents

Inhibiteurs spiro exo-aza de l'interaction ménine-mll

Info

Publication number
MA51337A
MA51337A MA051337A MA51337A MA51337A MA 51337 A MA51337 A MA 51337A MA 051337 A MA051337 A MA 051337A MA 51337 A MA51337 A MA 51337A MA 51337 A MA51337 A MA 51337A
Authority
MA
Morocco
Prior art keywords
menin
exo
spiro
mll interaction
aza
Prior art date
Application number
MA051337A
Other languages
English (en)
Inventor
Patrick René Angibaud
Wei Cai
Xuedong Dai
James Patrick Edwards
Liqiang Fu
Linglong Kong
Daniel Jason Krosky
Yingtao Liu
Geb Herkert Barbara Morschhäuser
Vineet Pande
Aaron Nathaniel Patrick
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Zhao-Kui Wan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA51337A publication Critical patent/MA51337A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051337A 2017-12-20 2018-12-19 Inhibiteurs spiro exo-aza de l'interaction ménine-mll MA51337A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017117536 2017-12-20
CN2018091521 2018-06-15

Publications (1)

Publication Number Publication Date
MA51337A true MA51337A (fr) 2020-10-28

Family

ID=66993097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051337A MA51337A (fr) 2017-12-20 2018-12-19 Inhibiteurs spiro exo-aza de l'interaction ménine-mll

Country Status (12)

Country Link
US (1) US20230039917A1 (fr)
EP (1) EP3728260A4 (fr)
JP (1) JP7307729B2 (fr)
KR (1) KR20200101389A (fr)
CN (1) CN111601807B (fr)
AU (1) AU2018389145B2 (fr)
BR (1) BR112020012461A2 (fr)
CA (1) CA3083624A1 (fr)
IL (1) IL275457A (fr)
MA (1) MA51337A (fr)
MX (1) MX2020006594A (fr)
WO (1) WO2019120209A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
CN110950818B (zh) * 2019-12-18 2021-12-28 浙江海翔药业股份有限公司 顺式-2,6-二甲基吗啉的纯化方法
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
BR112023021040A2 (pt) * 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (fr) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Dérivés spiro substitués
AR125866A1 (es) * 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
WO2013014162A1 (fr) 2011-07-28 2013-01-31 Cellzome Limited Analogues d'hétérocyclyl-pyrimidine en tant qu'inhibiteurs de jak
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
MA40957A (fr) 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (fr) 2015-06-04 2016-12-08 Kura Oncology, Inc. Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
WO2017161028A1 (fr) 2016-03-16 2017-09-21 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (fr) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2018024602A1 (fr) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro [4,4] nonanes
CA3033239A1 (fr) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs spiro bicycliques de l'interaction menine-mll
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
US11396517B1 (en) * 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction

Also Published As

Publication number Publication date
MX2020006594A (es) 2020-09-09
IL275457A (en) 2020-08-31
WO2019120209A1 (fr) 2019-06-27
BR112020012461A2 (pt) 2020-11-24
AU2018389145A1 (en) 2020-05-21
US20230039917A1 (en) 2023-02-09
EP3728260A4 (fr) 2021-08-11
RU2020123548A3 (fr) 2022-02-17
CN111601807A (zh) 2020-08-28
RU2020123548A (ru) 2022-01-20
AU2018389145B2 (en) 2023-02-02
CA3083624A1 (fr) 2019-06-27
CN111601807B (zh) 2023-03-31
JP2021506882A (ja) 2021-02-22
KR20200101389A (ko) 2020-08-27
JP7307729B2 (ja) 2023-07-12
EP3728260A1 (fr) 2020-10-28

Similar Documents

Publication Publication Date Title
EP3353328A4 (fr) Modulateurs de l'expression de kras
IL263586B (en) Inhibitors of the menin-mll interaction
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA46180A (fr) Analogues de l'amyline
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
PT3548033T (pt) Compostos e respectivos métodos de utilização
EP3353156A4 (fr) Inhibiteurs de l'autopalmitoylation du facteur de transcription tead
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
EP3732239A4 (fr) Composition de polyéthylène
EP3509581A4 (fr) Formulations de (r
IL275457A (en) Spiro exo-aza inhibitors of the MENIN-MLL interaction
IL272851A (en) Methods of using dipivefrin
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
PT3645518T (pt) Síntese de omecamtiv mecarbil
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
PT3457851T (pt) Derivados de sobetiroma
MA49006A (fr) Inhibiteurs d'ip6k
EP3632898A4 (fr) Antagoniste d'ep4
EP3449001A4 (fr) Inhibition de l'arnmi mir-22 par apt-110
EP3484854A4 (fr) Inhibiteurs de l'apoptose
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE